Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kezar Life Sciences, Inc. (KZR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a clinical-stage biopharmaceutical company listed on The Nasdaq Stock Market, Kezar uses these filings to report material events, governance decisions and financial information related to its development of novel small molecule therapeutics for immune-mediated diseases.
Recent Form 8-K filings highlighted in the company’s record include disclosures about its strategic review process, workforce restructuring, and the associated costs of exit or disposal activities. Kezar has reported a plan to reduce its workforce by approximately 70% in connection with its evaluation of strategic alternatives, with estimated one-time severance and related expenses. Another 8-K describes the repayment in full and termination of a loan and security agreement with Oxford Finance LLC, including the release of liens and security interests.
Additional 8-Ks document financial results announcements, such as quarterly updates on cash, cash equivalents and marketable securities, research and development and general and administrative expenses, and net loss. The company also files reports on shareholder rights matters, including the adoption and extension of a limited duration stockholder rights plan, and on annual meeting outcomes, where stockholders vote on director elections, advisory approval of executive compensation and ratification of the independent registered public accounting firm.
On Stock Titan, these filings are paired with AI-powered summaries that explain the core points of lengthy documents, helping readers quickly understand items such as restructuring charges, rights plan amendments or debt repayment terms. Users can monitor new 8-Ks as they are posted to EDGAR, review historical filings for context on Kezar’s governance and capital structure, and use the AI insights to interpret how reported events relate to the company’s clinical-stage business model.
Kezar Life Sciences, Inc. has terminated its headquarters lease early and announced leadership changes in connection with a pending sale. The company ended its lease for approximately 48,714 rentable square feet at 4000 Shoreline Court effective April 1, 2026, agreeing to pay the landlord about $2 million, including about $1.3 million in cash and surrender of about $0.7 million in security deposit.
On the same date, Kezar entered into separation agreements with its Chief Executive Officer Christopher J. Kirk, Ph.D., Chief Financial Officer and Secretary Marc L. Belsky, and Chief Operating Officer Mark Schiller, providing change-in-control style severance benefits and noting there were no disagreements with the company.
The filing also reiterates a previously announced Merger Agreement under which a subsidiary of Aurinia Pharma U.S., Inc. plans a tender offer in which each outstanding Kezar share would be converted into the right to receive $6.955 in cash plus one contingent value right, subject to the terms and conditions of the proposed transaction and related tender offer materials.
Tang Capital Management and related entities filed an amended Schedule 13D for Kezar Life Sciences. They report beneficial ownership of 664,314 shares of Kezar common stock, representing 9.0% of the outstanding shares based on 7,371,527 shares as of March 23, 2026.
On March 30, 2026, the reporting persons entered into a tender and support agreement related to an Agreement and Plan of Merger among Kezar and Aurinia-affiliated entities. Under this agreement, they agreed to tender all of their Kezar shares, subject to specified exceptions, and accepted restrictions on actions involving these shares. Concentra Biosciences also rescinded its prior proposal to acquire 100% of Kezar’s equity. The group reports no Kezar share transactions in the past 60 days.
Kezar Life Sciences agreed to be acquired by Aurinia Pharma U.S. through a cash tender offer followed by a merger. Aurinia will offer $6.955 in cash per Kezar share plus one contingent value right (CVR), giving stockholders potential additional cash tied to Kezar legacy assets and net cash above $50 million.
The tender offer will be launched within ten business days and kept open for 20 business days, with closing targeted for the second quarter of 2026, if customary conditions are met. A major stockholder holding about 9.0% of Kezar shares has agreed to tender, and Kezar’s board unanimously determined the deal is in the best interests of stockholders.
Kezar Life Sciences is a clinical-stage biotech company centered on zetomipzomib, a first‑in‑class selective immunoproteasome inhibitor for severe autoimmune diseases, particularly autoimmune hepatitis (AIH). After failing to align with the FDA on a registrational AIH trial in 2025, the company began restructuring and winding down operations while exploring strategic alternatives such as mergers, partnerships or asset sales.
In 2026, Kezar held a successful Type C meeting in which the FDA agreed on key elements of a potential global Phase 2b AIH trial, including treatment duration, endpoints and enrollment criteria, and provided guidance on safety monitoring. Prior AIH data from the PORTOLA Phase 2a trial showed higher rates of complete biochemical remission with steroid taper and some steroid‑free remission versus placebo, with mainly manageable injection‑related side effects.
The lupus nephritis PALIZADE Phase 2b trial was placed on clinical hold and later terminated after serious adverse events, including four fatalities, and Kezar subsequently stopped its Sec61 oncology program. In March 2026, the company sold all Sec61‑related assets, including KZR‑261, to Enodia Therapeutics. Kezar maintains key licenses with Onyx and a regional collaboration with Everest for zetomipzomib and holds a global patent estate extending into the 2030s. As of March 2026 the company had 9 employees and emphasizes significant business, clinical, regulatory and financing risks while it evaluates strategic options.
Kezar Life Sciences has sold its Sec61-based discovery and development program, including preclinical candidate KZR-261, to Enodia Therapeutics. Kezar received $800,000 at closing and is due an additional $200,000 tied to delivery of inventory or 45 days after closing.
The deal also includes up to $127,000,000 in development, regulatory and commercial milestone payments, plus single digit tiered royalties on future net sales of products derived from the acquired assets. Enodia assumed specified liabilities linked to transferred contracts and the acquired assets, while both parties agreed to customary indemnification capped at $1,000,000 for non-fraud losses.
The transaction carves out only the Sec61 program; Kezar retained its zetomipzomib program, employee contracts, cash, receivables, real property and equipment. A joint press release announcing the deal was issued on March 12, 2026.
Kezar Life Sciences, Inc. received an amended Schedule 13G/A from Stonepine-affiliated investors reporting a modest ownership position in its common stock. Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico together report beneficial ownership of 156,179 shares, representing 2.1% of the class.
All reporting persons have shared voting and dispositive power over these shares and no sole power. They indicate the securities were not acquired and are not held to change or influence control of Kezar Life Sciences and state their ownership is below 5% of the outstanding common stock.
Kezar Life Sciences, Inc. received an updated ownership disclosure from BML Investment Partners, L.P. in Amendment No. 2 to a Schedule 13G. As of the event date of December 31, 2025, BML Investment Partners reported beneficial ownership of 720,787 shares of Kezar common stock, representing 9.8% of the class.
The filing shows BML Investment Partners has shared voting and dispositive power over all 720,787 shares and no sole power. BML Investment Partners is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC, managed by Braden M. Leonard, who is deemed an indirect owner. The reporting persons certify the shares are held on a passive basis, not to change or influence control of Kezar.
Kezar Life Sciences (KZR) reported Q3 2025 results with a net loss of $11.2 million (loss per share $1.53), reflecting sharply lower operating expenses as R&D declined to $6.9 million from $16.2 million a year ago. Cash, cash equivalents and marketable securities totaled $90.2 million as of September 30, 2025, and total stockholders’ equity was $83.0 million.
Management stated existing liquidity is expected to fund operations for at least 12 months. After quarter end, the company repaid $6.3 million to fully retire its Oxford Finance loan and extended its stockholder rights plan. Kezar is exploring strategic alternatives and reduced its workforce by ~70%, estimating $6.0 million in severance and related cash costs, largely recognized in Q4 2025. The company also disclosed it was unable to align with the FDA on a potential registrational AIH study and the FDA cancelled a planned Type C meeting.
Shares outstanding were 7,323,106 as of September 30, 2025; 7,323,156 were outstanding as of November 10, 2025.
Kezar Life Sciences (KZR) announced a major restructuring, reducing its workforce by approximately 31 employees, or about 70%, in connection with its evaluation of strategic alternatives.
The company estimates cash expenditures of about $6.0 million for one-time severance, benefits, and related costs, with the majority of these charges expected to be recognized in the fourth quarter of 2025. Management noted that actual costs could differ materially and that additional charges may arise depending on subsequent events.
Kezar Life Sciences (KZR) repaid its debt under a prior loan agreement and terminated the facility. On October 20, 2025, the company used cash on hand to repay $6.3 million, covering the aggregate outstanding amount, accrued interest, and exit fees under its November 4, 2021 Loan and Security Agreement with Oxford Finance LLC and related lenders. Following repayment, the agreement was terminated and all liens and security interests were released.
This action removes obligations tied to the loan and releases collateral, simplifying Kezar’s capital structure.